{"id":15597,"date":"2025-11-26T17:16:29","date_gmt":"2025-11-26T11:46:29","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15597"},"modified":"2026-01-23T15:02:46","modified_gmt":"2026-01-23T09:32:46","slug":"invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Invicta Diagnostic IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p>India\u2019s healthcare and diagnostics sector has been growing steadily, supported by rising health awareness, urbanisation, and increased spending on preventive care. Against this backdrop, Invicta Diagnostic Limited is coming out with its IPO on December 1, 2025, giving investors a chance to participate in a diagnostics business that operates on a hub and spoke model in the Mumbai Metropolitan Region.<\/p>\n<p>Below is a detailed insight into Invicta Diagnostic, its IPO structure, financial performance, and growth plans.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Invicta_Diagnostic_Ltd\"><\/span><strong>About Invicta Diagnostic Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in January 2021, Invicta Diagnostic Limited provides integrated radiology and pathology solutions under the brand &#8220;PC Diagnostics&#8221;. The company focuses on both imaging and laboratory diagnostics within the Mumbai Metropolitan Region, following a hub-and-spoke model.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Network_structure_as_of_May_31_2025\"><\/span><strong>Network structure (as of May 31, 2025):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Flagship hub<\/strong> in <strong>Thane West<\/strong>\n<ul>\n<li>Full-spectrum pathology<\/li>\n<li>Advanced radiology, including CT and MRI<\/li>\n<\/ul>\n<\/li>\n<li><strong>Three additional hubs<\/strong>\n<ul>\n<li>Bhayandar<\/li>\n<li>Byculla<\/li>\n<li>Marol<br \/>\nThese hubs provide specialised diagnostic services.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Four spoke centres<\/strong>\n<ul>\n<li>Lower Parel<\/li>\n<li>Sewri<\/li>\n<li>Mazgaon<\/li>\n<li>Kalwa<br \/>\nThese focus on basic imaging, like X-ray and ultrasound and sample collection.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Test_portfolio\"><\/span><strong>Test portfolio:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Around 60 routine and 487 specialised pathology tests<\/li>\n<li>Around 96 basic and 130 advanced radiology tests<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Service_offerings_include\"><\/span><strong>Service offerings include:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Routine tests:<\/strong> CBC, lipid profile, LFT, KFT, thyroid panels and other standard investigations<\/li>\n<li><strong>Specialised tests:<\/strong> Molecular diagnostics, immunoassays, infectious disease markers such as dengue and COVID-19, cancer markers and genetic panels<\/li>\n<li><strong>Teleradiology and imaging:<\/strong> CT, MRI, ultrasound and X-ray reporting through in-house radiologists<\/li>\n<li><strong>Sample collection network:<\/strong> Home collection via phlebotomists and partner collection centres<\/li>\n<\/ul>\n<p>As of May 31, 2025, the company has:<\/p>\n<ul>\n<li>5 laboratory doctors<\/li>\n<li>20 radiologists<\/li>\n<li>127 technical staff<\/li>\n<li>105 permanent employees<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Promoters\"><\/span><strong>Promoters:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Dr. Ketan Jayantilal Jain<\/li>\n<li>Dr. Sanket Vinod Jain<\/li>\n<li>Rohit Prakash Srivastava<\/li>\n<li>Badal Kailash Naredi<\/li>\n<li>Jayesh Prakash Jain<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Strengths\"><\/span><strong>Competitive Strengths:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Expanding presence in MMR, especially in radiology<\/li>\n<li>One-stop diagnostics provider at relatively affordable pricing<\/li>\n<li>Strong IT infrastructure and technology-driven operations<\/li>\n<li>Hub and spoke delivery model<\/li>\n<li>Experienced management and medical team<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Invicta_Diagnostic_IPO_Details\"><\/span><strong>Invicta Diagnostic IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/www.torusdigital.com\/ipo\/invicta-diagnostic-ltd-ipo\">Invicta Diagnostic IPO<\/a> is a book-built issue aggregating up to \u20b928.12 crore, entirely a fresh issue of equity shares.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Important_IPO_Timeline\"><\/span><strong>Important IPO Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Event<\/strong><\/td>\n<td><strong>Date (Tentative)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>IPO Open Date<\/td>\n<td>December 1, 2025 (Mon)<\/td>\n<\/tr>\n<tr>\n<td>IPO Close Date<\/td>\n<td>December 3, 2025 (Wed)<\/td>\n<\/tr>\n<tr>\n<td>Basis of Allotment<\/td>\n<td>December 4, 2025 (Thu)<\/td>\n<\/tr>\n<tr>\n<td>Initiation of Refunds<\/td>\n<td>December 5, 2025 (Fri)<\/td>\n<\/tr>\n<tr>\n<td>Credit of Shares to Demat<\/td>\n<td>December 5, 2025 (Fri)<\/td>\n<\/tr>\n<tr>\n<td>Listing Date<\/td>\n<td>December 8, 2025 (Mon)<\/td>\n<\/tr>\n<tr>\n<td>Cut off time for UPI mandate confirmation<\/td>\n<td>5 PM on December 3, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_IPO_Details\"><\/span><strong>Key IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Here is the table on the Invicta Diagnostic IPO review:<\/p>\n<table>\n<tbody>\n<tr>\n<td>IPO Date<\/td>\n<td>December 1, 2025 to December 3, 2025<\/td>\n<\/tr>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b910\u00a0per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b980 to \u20b985 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>1,600 Shares<\/td>\n<\/tr>\n<tr>\n<td>Sale Type<\/td>\n<td>Fresh Capital<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>33,08,800\u00a0shares<br \/>\n(aggregating up to \u20b928.12\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding\u00a0IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>NSE SME<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Pre Issue<\/td>\n<td>92,63,173\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Post Issue<\/td>\n<td>1,25,71,973\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Book Running Lead Manager<\/td>\n<td>Socradamus Capital Pvt.Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Registrar<\/td>\n<td>Bigshare Services Pvt.Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Market Maker<\/td>\n<td>Nikunj Stock Brokers Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"IPO_Reservation\"><\/span><strong>IPO Reservation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Investor Category<\/strong><\/td>\n<td><strong>Shares Offered<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>QIB<\/td>\n<td>Not more than 50% of Net Issue<\/td>\n<\/tr>\n<tr>\n<td>Retail<\/td>\n<td>Not less than 35% of Net Issue<\/td>\n<\/tr>\n<tr>\n<td>NII<\/td>\n<td>Not less than 15% of Net Issue<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Lot_Size_of_Invicta_Diagnostic_IPO\"><\/span><strong>Lot Size of Invicta Diagnostic IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Here is the table of lot sizes for each category of investors:<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>Application<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount (at \u20b985)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Individual investors (Retail) (Min)<\/td>\n<td>2<\/td>\n<td>3,200<\/td>\n<td>\u20b92,72,000<\/td>\n<\/tr>\n<tr>\n<td>Individual investors (Retail) (Max)<\/td>\n<td>2<\/td>\n<td>3,200<\/td>\n<td>\u20b92,72,000<\/td>\n<\/tr>\n<tr>\n<td>S HNI (Min)<\/td>\n<td>3<\/td>\n<td>4,800<\/td>\n<td>\u20b94,08,000<\/td>\n<\/tr>\n<tr>\n<td>S HNI (Max)<\/td>\n<td>7<\/td>\n<td>11,200<\/td>\n<td>\u20b99,52,000<\/td>\n<\/tr>\n<tr>\n<td>B HNI (Min)<\/td>\n<td>8<\/td>\n<td>12,800<\/td>\n<td>\u20b910,88,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Invicta_Diagnostic_IPO_Promoter_Holding\"><\/span><strong>Invicta Diagnostic IPO Promoter Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><\/td>\n<td><strong>Pre Issue<\/strong><\/td>\n<td><strong>Post Issue<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoter Holding<\/td>\n<td>90.52%<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Invicta_Diagnostic_Ltd_Financials\"><\/span><strong>Invicta Diagnostic Ltd. Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The company has reported strong growth in both revenue and profitability. Between FY2024 and FY2025, revenue increased by 90 % and profit after tax rose by 30 %.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_Company_Financials\"><\/span><strong>Key Company Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Amounts in \u20b9 Crore<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>30 Sep 2025<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Assets<\/td>\n<td>34.90<\/td>\n<td>21.22<\/td>\n<td>15.89<\/td>\n<\/tr>\n<tr>\n<td>Total Income<\/td>\n<td>17.08<\/td>\n<td>30.18<\/td>\n<td>15.90<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax<\/td>\n<td>4.08<\/td>\n<td>4.93<\/td>\n<td>3.81<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>6.77<\/td>\n<td>9.20<\/td>\n<td>7.09<\/td>\n<\/tr>\n<tr>\n<td>NET Worth<\/td>\n<td>23.68<\/td>\n<td>13.60<\/td>\n<td>8.67<\/td>\n<\/tr>\n<tr>\n<td>Reserves and Surplus<\/td>\n<td>14.42<\/td>\n<td>5.18<\/td>\n<td>8.54<\/td>\n<\/tr>\n<tr>\n<td>Total Borrowing<\/td>\n<td>3.72<\/td>\n<td>3.54<\/td>\n<td>3.81<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_KPI\"><\/span><strong>Key Performance Indicators (KPI)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>KPI as of March 31, 2025<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>KPI<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>ROE<\/td>\n<td>44.28%<\/td>\n<\/tr>\n<tr>\n<td>ROCE<\/td>\n<td>42.00%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.26<\/td>\n<\/tr>\n<tr>\n<td>RoNW<\/td>\n<td>36.25%<\/td>\n<\/tr>\n<tr>\n<td>PAT Margin<\/td>\n<td>16.38%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>30.57%<\/td>\n<\/tr>\n<tr>\n<td>Price to Book Value<\/td>\n<td>5.26<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b9106.86 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_and_Valuation\"><\/span><strong>Earnings and Valuation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>Pre IPO<\/strong><\/td>\n<td><strong>Post IPO<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>EPS (\u20b9)<\/td>\n<td>5.32<\/td>\n<td>6.50<\/td>\n<\/tr>\n<tr>\n<td>P E (x)<\/td>\n<td>15.97<\/td>\n<td>13.08<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Objects_of_the_Invicta_Diagnostic_IPO\"><\/span><strong>Objects of the Invicta Diagnostic IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company proposes to utilise the net proceeds from the issue towards the following objectives:<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>S.No.<\/strong><\/td>\n<td><strong>Objects of the Issue<\/strong><\/td>\n<td><strong>Expected Amount (\u20b9 in Crore)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Funding capital expenditure for the purchase of medical equipment toward the establishment of five new diagnostic centres in Maharashtra<\/td>\n<td>21.11<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>General corporate purposes<\/td>\n<td>Balance from proceeds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Invicta_Diagnostic_Ltd_Industry_Outlook\"><\/span><strong>Invicta Diagnostic Ltd.: Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>The Indian diagnostics industry has been witnessing steady growth driven by rising lifestyle diseases, increasing health awareness, insurance penetration and urban population growth.<\/li>\n<li>Demand for integrated diagnostic services that combine radiology and pathology under one roof is increasing, particularly in urban clusters such as Mumbai.<\/li>\n<li>Hub and spoke models help improve asset utilisation of high-cost radiology equipment like CT and MRI, while spoke centres and home collection expand access and convenience for patients.<\/li>\n<li>Technology adoption in teleradiology, electronic reporting and digital platforms supports scalability and operational efficiency for players like Invicta Diagnostic.<\/li>\n<\/ul>\n<p>Invicta\u2019s focus on the Mumbai Metropolitan Region, its expanding network of hubs and spokes, and its emphasis on specialised tests and advanced imaging place it in a favourable position to benefit from these trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Invicta_Diagnostic_IPO_Peer_Comparison\"><\/span><strong>Invicta Diagnostic IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Invicta Diagnostic&#8217;s IPO can be compared with peers like <a href=\"https:\/\/www.torusdigital.com\/stocks\/krsnaa-diagnostics-ltd-share-price\">Krsnaa Diagnostics Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/vijaya-diagnostic-centre-ltd-share-price\">Vijaya Diagnostic Centre Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/metropolis-healthcare-ltd-share-price\">Metropolis Healthcare Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/dr-lal-pathlabs-ltd-share-price\">Dr. Lal PathLabs Ltd<\/a>, and Agilus Diagnostics Ltd. Reviewing these companies helps investors understand Invicta Diagnostic\u2019s position within the diagnostics and <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/healthcare\">healthcare services sector<\/a> and make informed investment decisions.<\/p>\n<p><em><strong>People Also Read:<\/strong><\/em><\/p>\n<ul>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/clear-secured-services-ipo-opens-key-details-investors-shouldnt-miss\/\">Clear Secured Services IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/ravelcare-ipo-opens-key-details-investors-shouldnt-miss\/\">Ravelcare IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/logiciel-solutions-ipo-opens-key-details-investors-shouldnt-miss\/\">Logiciel Solutions IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/exato-technologies-ipo-opens-key-details-investors-shouldnt-miss\/\">Exato Technologies IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/purple-wave-infocom-ipo-opens-key-details-investors-shouldnt-miss\/\">Purple Wave Infocom IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Invicta Diagnostic Ltd presents an interesting IPO opportunity in the diagnostics and healthcare services space. The company has:<\/p>\n<ul>\n<li>A focused presence in the Mumbai Metropolitan Region<\/li>\n<li>An integrated pathology and radiology model using a hub and spoke network<\/li>\n<li>Strong growth in revenue and profits in the reported periods<\/li>\n<li>Healthy margins and return ratios, with <strong><a href=\"https:\/\/www.torusdigital.com\/toruscope\/stocks\/what-is-return-on-equity\/\">ROE<\/a><\/strong> and ROCE above 40%<\/li>\n<\/ul>\n<p>At the same time, investors should consider key risks such as:<\/p>\n<ul>\n<li>Geographic concentration in a single metro region<\/li>\n<li>Competitive intensity from larger national diagnostic chains and hospital-backed labs<\/li>\n<li>Dependence on the continued execution of its expansion plan for new centres<\/li>\n<\/ul>\n<p>Based on its recent financial data, the issue valuation (post-issue P\/E of about 21.68 times FY2025 earnings) appears in the higher band for SME listings, so it may suit investors who have a higher risk appetite, longer investment horizon, and interest in healthcare services.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on\u202f<a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO<\/a> listings\u202fto stay updated on the latest market offerings.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15597 \"  data-post-id=\"15597\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--half-highlight js-rmp-replace-half-star\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">3.7<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">6<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a aria-label=\"Share on Facebook\" href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Finvicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Invicta+Diagnostic+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a aria-label=\"Share on X\" href=\"\/\/twitter.com\/intent\/tweet?text=Invicta+Diagnostic+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Finvicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a aria-label=\"Share on Whatsapp\" href=\"https:\/\/api.whatsapp.com\/send?text=Invicta+Diagnostic+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Finvicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a aria-label=\"Share on LinkedIn\" href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Finvicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Invicta+Diagnostic+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] India\u2019s healthcare and diagnostics sector has been growing steadily, supported by rising health awareness, urbanisation, and increased spending on preventive care. Against this backdrop, Invicta Diagnostic Limited is coming out with its IPO on December 1, 2025, giving investors a chance to participate in a diagnostics business that operates on","protected":false},"author":1,"featured_media":14024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-15597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invicta Diagnostic IPO Opens: What Investors Need To Know<\/title>\n<meta name=\"description\" content=\"Invicta Diagnostic IPO offers investors exposure to a fast-growing Mumbai-based diagnostics company with integrated pathology and radiology services. Read on for key IPO details, financials, objectives, and important dates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invicta Diagnostic IPO Opens: What Investors Need To Know\" \/>\n<meta property=\"og:description\" content=\"Invicta Diagnostic IPO offers investors exposure to a fast-growing Mumbai-based diagnostics company with integrated pathology and radiology services. Read on for key IPO details, financials, objectives, and important dates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T11:46:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T09:32:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invicta Diagnostic IPO Opens: What Investors Need To Know","description":"Invicta Diagnostic IPO offers investors exposure to a fast-growing Mumbai-based diagnostics company with integrated pathology and radiology services. Read on for key IPO details, financials, objectives, and important dates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Invicta Diagnostic IPO Opens: What Investors Need To Know","og_description":"Invicta Diagnostic IPO offers investors exposure to a fast-growing Mumbai-based diagnostics company with integrated pathology and radiology services. Read on for key IPO details, financials, objectives, and important dates.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-11-26T11:46:29+00:00","article_modified_time":"2026-01-23T09:32:46+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Invicta Diagnostic IPO Opens: What Investors Need To Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","datePublished":"2025-11-26T11:46:29+00:00","dateModified":"2026-01-23T09:32:46+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Invicta Diagnostic IPO offers investors exposure to a fast-growing Mumbai-based diagnostics company with integrated pathology and radiology services. Read on for key IPO details, financials, objectives, and important dates.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/invicta-diagnostics-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Invicta Diagnostic IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15597"}],"version-history":[{"count":3,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15597\/revisions"}],"predecessor-version":[{"id":16182,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15597\/revisions\/16182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14024"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}